To delineate the functional relevance of PTN in tumor initiation versus tumor progression, we utilized a mouse monoclonal antibody, 3B10, that has been reported to neutralize PTN activity (US patent no. 20140294845A1). This evidence concerns the gene PTN and neoplasm.